Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4449510
Max Phase: Preclinical
Molecular Formula: C21H33N5O10
Molecular Weight: 515.52
Molecule Type: Unknown
Associated Items:
ID: ALA4449510
Max Phase: Preclinical
Molecular Formula: C21H33N5O10
Molecular Weight: 515.52
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H]1CCN[C@H]([C@H](O[C@@H]2O[C@H](CN)[C@@H](O)[C@H]2O)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)C1
Standard InChI: InChI=1S/C21H33N5O10/c1-8(27)24-9-2-4-23-10(6-9)17(36-20-16(32)13(29)11(7-22)34-20)18-14(30)15(31)19(35-18)26-5-3-12(28)25-21(26)33/h3,5,9-11,13-20,23,29-32H,2,4,6-7,22H2,1H3,(H,24,27)(H,25,28,33)/t9-,10+,11-,13-,14+,15-,16-,17+,18+,19-,20+/m1/s1
Standard InChI Key: KXLIIUQIICVMFD-LCTOQHDJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 515.52 | Molecular Weight (Monoisotopic): 515.2227 | AlogP: -4.80 | #Rotatable Bonds: 7 |
Polar Surface Area: 230.62 | Molecular Species: BASE | HBA: 13 | HBD: 8 |
#RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 9 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.70 | CX Basic pKa: 9.02 | CX LogP: -5.43 | CX LogD: -8.00 |
Aromatic Rings: 1 | Heavy Atoms: 36 | QED Weighted: 0.17 | Np Likeness Score: 1.21 |
1. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G.. (2019) Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY., 171 [PMID:30933853] [10.1016/j.ejmech.2019.01.071] |
Source(1):